Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAL 801 CL (Epinastine) Dry Syrup in Pediatric Atopic Dermatitis
NCT02182570Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2001
- Primary completion
- Feb 2002
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of epinastine hydrochloride in atopic dermatitis (AD), sponsored by Boehringer Ingelheim. Started Jun 2001; status: completed.
02
Drugs
epinastine hydrochloride
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02182570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182570.